Literature DB >> 19733822

The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan.

Li-Chia Chen1, Ellen I Schafheutle, Peter R Noyce.   

Abstract

BACKGROUND: Taiwan's National Health Insurance's (NHI) generous coverage and patients' freedom to access different tiers of medical facilities have resulted in accelerating outpatient care utilization and costs. To deter nonessential visits and encourage initial contact in primary care (physician clinics), a differential co-payment was introduced on 15th July 2005. Under this, patients pay more for outpatient consultations at "higher tiers" of medical facilities (local community hospitals, regional hospitals, medical centers), particularly if accessed without referral.
OBJECTIVES: This study explored the impact of this policy on outpatient medical activities and expenditures, different co-payment groups, and tiers of medical facilities.
METHODS: A segmented time-series analysis on regional weekly outpatient medical claims (January 2004 to July 2006) was conducted. Outcome variables (number of visits, number of outpatients, total cost of outpatient care) and variables for cost structure were stratified by tiers of medical facilities and co-payment groups. Analysis used the auto-regressive integrated moving-average model in STATA 9.0.
RESULTS: The overall number of outpatient visits significantly decreased after policy implementation due to a reduction in the number of patients using outpatient facilities, but total costs of care remained unchanged. The policy had its greatest impact on the number of visits to regional and local community hospitals but had no influence on those to the medical centers. Medical utilization in physician clinics decreased due to an audit of reimbursement declarations. Overall, the policy failed to encourage referrals from primary care to higher tiers because there was no obvious shifting of medical utilization and costs reversely.
CONCLUSIONS: Differential co-payment policy decreased total medication utilization but not costs to NHI. The results suggest that the increased level of co-payment charge and the strategy of a single cost-sharing policy are not sufficient to promote referrals within the system. To achieve an effective co-payment policy, further research is needed to explore how patients' out-of-pocket payment affects medical utilization and which forces (not susceptible to co-payment) act in tertiary facilities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733822     DOI: 10.1016/j.sapharm.2008.08.003

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  5 in total

Review 1.  Does charging different user fees for primary and secondary care affect first-contacts with primary healthcare? A systematic review.

Authors:  Thomas Hone; John Tayu Lee; Azeem Majeed; Lesong Conteh; Christopher Millett
Journal:  Health Policy Plan       Date:  2017-06-01       Impact factor: 3.344

2.  Health policies on dialysis modality selection: a nationwide population cohort study.

Authors:  Yi-Chun Lin; Yen-Chung Lin; Chih-Chin Kao; Hsi-Hsien Chen; Chih-Cheng Hsu; Mai-Szu Wu
Journal:  BMJ Open       Date:  2017-01-11       Impact factor: 2.692

3.  Characteristics of Non-Emergent Visits in Emergency Departments: Profiles and Longitudinal Pattern Changes in Taiwan, 2000-2010.

Authors:  Liang-Chung Huang; Wu-Fu Chung; Shih-Wei Liu; Jau-Ching Wu; Li-Fu Chen; Yu-Chun Chen
Journal:  Int J Environ Res Public Health       Date:  2019-06-05       Impact factor: 3.390

4.  Patterns of nonemergent visits to different healthcare facilities on the same day: a nationwide analysis in Taiwan.

Authors:  Meng-Hsuan Wu; Meng-Ju Wu; Li-Fang Chou; Tzeng-Ji Chen
Journal:  ScientificWorldJournal       Date:  2014-04-22

5.  Age Structural Transitions and Copayment Policy Effectiveness: Evidence from Taiwan's National Health Insurance System.

Authors:  Ya-Ling Lin; Wen-Yi Chen; Shwn-Huey Shieh
Journal:  Int J Environ Res Public Health       Date:  2020-06-12       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.